Trump Again Promises Lower Drug Prices By 'Cutting Out Middlemen' Like UnitedHealth, CVS: Will It Work This Time?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2025
0mins
Source: Benzinga
Executive Order on Drug Prices: President Trump signed an executive order to reduce U.S. prescription drug prices by tying them to the lowest prices in comparable foreign countries, allowing for direct purchases from manufacturers and threatening the pharmacy benefit manager (PBM) business model.
Reactions and Market Impact: The order received mixed reactions, with concerns about its legal enforceability and potential court challenges, leading to fluctuations in pharmaceutical stock prices, particularly affecting companies associated with PBMs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise
16 Analyst Rating
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 284.040
Low
300.00
Averages
335.63
High
378.00
Current: 284.040
Low
300.00
Averages
335.63
High
378.00
About CI
The Cigna Group is a global health company. The Company has two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to customers and clients. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help the clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cigna Group Rated Among Top Fortune 500 Stocks
- Strong Earnings Beat: Cigna Group reported an adjusted EPS of $7.79 for Q1 2023, reflecting a 16% year-over-year growth, while revenue reached $68.5 billion, up 4.7%, indicating robust financial performance that boosts market confidence in future growth.
- Price Target Increase: Barclays raised Cigna's price target from $303 to $310, maintaining an 'Overweight' rating, which represents an almost 10% upside from current levels, reflecting analysts' optimistic outlook on the company's future performance.
- Exit from Subsidized Plans: Cigna announced its exit from subsidized plans under the Affordable Care Act by year-end, a strategic decision that may impact market share but aims to optimize its product portfolio and enhance overall profitability.
- Upgraded Full-Year Outlook: Cigna raised its full-year 2026 consolidated adjusted EPS outlook to at least $30.35, up from the previous guidance of $30.25 and slightly above the consensus of $30.33, demonstrating the company's confidence in its future earnings.
See More
Amazon's New Logistics Initiative Shakes Market
- Increased Market Competition: Amazon's announcement of a new initiative allowing external businesses to utilize its supply chain for deliveries led to significant stock declines for UPS and FedEx, dropping over 10% and 9% respectively, indicating investor concerns about intensified competition in the logistics sector.
- Strong Sales Growth: Palantir reported an impressive 85% revenue growth in Q1, with net income approximately quadrupling year-over-year, showcasing its robust performance in the defense technology sector and projecting a doubling of its U.S. business in the coming year.
- Tesla and SEC Settlement: Tesla CEO Elon Musk reached a settlement with the SEC, agreeing to pay $1.5 million in penalties over allegations of failing to disclose his Twitter stake prior to acquisition, although this minor fine is not expected to have a significant financial impact on the company.
- GLP-1 Market Dynamics: Novo Nordisk's Wegovy pill has rapidly gained tens of thousands of new users within four months of launch, while Eli Lilly's competing Foundayo has seen a more modest uptake, reflecting a shift in market demand for weight-loss medications.
See More
Amazon's New Logistics Initiative Shakes Market
- Market Uncertainty Intensifies: Rising tensions in the Middle East have led to surging oil prices, causing the Dow Jones Industrial Average to drop over 550 points on Monday, marking its worst performance in more than a month, which has left investors concerned about future market sentiment.
- Palantir Surpasses Expectations: Palantir reported an 85% revenue growth in Q1, with net income nearly quadrupling year-over-year, and anticipates its U.S. business will double again next year, raising its full-year free cash flow guidance to $4.2 billion to $4.4 billion, indicating strong market demand and growth potential.
- Tesla Settles with SEC: Tesla CEO Elon Musk has agreed to pay $1.5 million to the SEC to settle allegations of failing to disclose his stake in Twitter before its acquisition, which, if approved by the judge, could alleviate legal risks for Musk and potentially have a positive impact on Tesla's stock price.
- Amazon's New Logistics Initiative: Amazon announced a new initiative allowing external businesses to utilize its supply chain networks for deliveries, which has raised concerns about increased competition with UPS and FedEx, leading to stock declines of over 10% and 9% respectively, reflecting market apprehension about the new competitive landscape.
See More
Health Insurers Show Strong Q1 Performance Amid Cost Challenges
- Strong Q1 Results: Major health insurers like UnitedHealth, Elevance, Cigna, and Humana exceeded expectations, boosting investor sentiment despite rising medical costs, reflecting effective strategies in pricing and cost control.
- Increased Medical Reserves: Analysts noted that insurers have strengthened medical reserves, providing a cushion for future claims, a strategy that could imply positive earnings implications for 2026, although the real data from Q2 remains crucial.
- Market Adjustment Strategies: Companies have successfully reduced medical loss ratios by exiting unprofitable markets and adjusting pricing and benefits of medical plans, demonstrating effective responses to increased demand for medical services post-pandemic, thereby enhancing market competitiveness.
- Critical Future Outlook: The second quarter will serve as a true test for insurers, as more claims data becomes available, investors will closely monitor medical loss ratios and changes in full-year outlooks to assess whether companies can sustain current growth momentum.
See More
Sierra Raises Nearly $1 Billion Amid Intensifying AI Market Competition
- Record Funding Round: Sierra has raised $950 million in its latest funding round, achieving a post-money valuation of $15.8 billion, which underscores the strong interest and confidence from investors in the AI sector, particularly in a rapidly intensifying competitive landscape.
- Rapid Revenue Growth: The company surpassed $150 million in annual recurring revenue (ARR) within eight quarters, a growth trajectory unprecedented in traditional software, highlighting the intense market demand for its AI customer service agents.
- Significant Market Opportunity: Taylor estimates that $400 billion is spent annually on customer service, and as enterprises increasingly shift towards AI agents, Sierra is positioned to capitalize on this substantial market opportunity by offering more efficient service experiences.
- Strategic Expansion Plans: With the new funding, Sierra aims to solidify its market leadership; Taylor noted that despite fierce competition, the company is multiples larger than its nearest rivals and will continue to invest aggressively to maintain its competitive edge.
See More
AI Startup Sierra Raises $950 Million in Series E Funding
- Record Funding Round: Sierra raised $950 million in its latest funding round, pushing its valuation from $10 billion to $15.8 billion, highlighting investors' strong interest in the AI sector and their pursuit of emerging market leaders.
- Diverse Clientele: The startup serves major enterprises like Prudential, Cigna, Blue Cross Blue Shield, and Rocket Mortgage, reaching over 40% of Fortune 50 companies, which underscores its market leadership in AI customer service.
- Rapid Revenue Growth: Sierra achieved over $150 million in annual recurring revenue (ARR) within eight quarters, an unprecedented growth rate in traditional software, reflecting intense market demand for its offerings.
- Expansive Market Potential: Founder Bret Taylor estimates that $400 billion is spent annually on customer service, and as AI agents become more prevalent, Sierra is focused on maintaining its competitive edge in an increasingly crowded market.
See More
Cigna Group Rated Among Top Fortune 500 Stocks
- Strong Earnings Beat: Cigna Group reported an adjusted EPS of $7.79 for Q1 2023, reflecting a 16% year-over-year growth, while revenue reached $68.5 billion, up 4.7%, indicating robust financial performance that boosts market confidence in future growth.
- Price Target Increase: Barclays raised Cigna's price target from $303 to $310, maintaining an 'Overweight' rating, which represents an almost 10% upside from current levels, reflecting analysts' optimistic outlook on the company's future performance.
- Exit from Subsidized Plans: Cigna announced its exit from subsidized plans under the Affordable Care Act by year-end, a strategic decision that may impact market share but aims to optimize its product portfolio and enhance overall profitability.
- Upgraded Full-Year Outlook: Cigna raised its full-year 2026 consolidated adjusted EPS outlook to at least $30.35, up from the previous guidance of $30.25 and slightly above the consensus of $30.33, demonstrating the company's confidence in its future earnings.
See More
Amazon's New Logistics Initiative Shakes Market
- Increased Market Competition: Amazon's announcement of a new initiative allowing external businesses to utilize its supply chain for deliveries led to significant stock declines for UPS and FedEx, dropping over 10% and 9% respectively, indicating investor concerns about intensified competition in the logistics sector.
- Strong Sales Growth: Palantir reported an impressive 85% revenue growth in Q1, with net income approximately quadrupling year-over-year, showcasing its robust performance in the defense technology sector and projecting a doubling of its U.S. business in the coming year.
- Tesla and SEC Settlement: Tesla CEO Elon Musk reached a settlement with the SEC, agreeing to pay $1.5 million in penalties over allegations of failing to disclose his Twitter stake prior to acquisition, although this minor fine is not expected to have a significant financial impact on the company.
- GLP-1 Market Dynamics: Novo Nordisk's Wegovy pill has rapidly gained tens of thousands of new users within four months of launch, while Eli Lilly's competing Foundayo has seen a more modest uptake, reflecting a shift in market demand for weight-loss medications.
See More
Amazon's New Logistics Initiative Shakes Market
- Market Uncertainty Intensifies: Rising tensions in the Middle East have led to surging oil prices, causing the Dow Jones Industrial Average to drop over 550 points on Monday, marking its worst performance in more than a month, which has left investors concerned about future market sentiment.
- Palantir Surpasses Expectations: Palantir reported an 85% revenue growth in Q1, with net income nearly quadrupling year-over-year, and anticipates its U.S. business will double again next year, raising its full-year free cash flow guidance to $4.2 billion to $4.4 billion, indicating strong market demand and growth potential.
- Tesla Settles with SEC: Tesla CEO Elon Musk has agreed to pay $1.5 million to the SEC to settle allegations of failing to disclose his stake in Twitter before its acquisition, which, if approved by the judge, could alleviate legal risks for Musk and potentially have a positive impact on Tesla's stock price.
- Amazon's New Logistics Initiative: Amazon announced a new initiative allowing external businesses to utilize its supply chain networks for deliveries, which has raised concerns about increased competition with UPS and FedEx, leading to stock declines of over 10% and 9% respectively, reflecting market apprehension about the new competitive landscape.
See More
Health Insurers Show Strong Q1 Performance Amid Cost Challenges
- Strong Q1 Results: Major health insurers like UnitedHealth, Elevance, Cigna, and Humana exceeded expectations, boosting investor sentiment despite rising medical costs, reflecting effective strategies in pricing and cost control.
- Increased Medical Reserves: Analysts noted that insurers have strengthened medical reserves, providing a cushion for future claims, a strategy that could imply positive earnings implications for 2026, although the real data from Q2 remains crucial.
- Market Adjustment Strategies: Companies have successfully reduced medical loss ratios by exiting unprofitable markets and adjusting pricing and benefits of medical plans, demonstrating effective responses to increased demand for medical services post-pandemic, thereby enhancing market competitiveness.
- Critical Future Outlook: The second quarter will serve as a true test for insurers, as more claims data becomes available, investors will closely monitor medical loss ratios and changes in full-year outlooks to assess whether companies can sustain current growth momentum.
See More
Sierra Raises Nearly $1 Billion Amid Intensifying AI Market Competition
- Record Funding Round: Sierra has raised $950 million in its latest funding round, achieving a post-money valuation of $15.8 billion, which underscores the strong interest and confidence from investors in the AI sector, particularly in a rapidly intensifying competitive landscape.
- Rapid Revenue Growth: The company surpassed $150 million in annual recurring revenue (ARR) within eight quarters, a growth trajectory unprecedented in traditional software, highlighting the intense market demand for its AI customer service agents.
- Significant Market Opportunity: Taylor estimates that $400 billion is spent annually on customer service, and as enterprises increasingly shift towards AI agents, Sierra is positioned to capitalize on this substantial market opportunity by offering more efficient service experiences.
- Strategic Expansion Plans: With the new funding, Sierra aims to solidify its market leadership; Taylor noted that despite fierce competition, the company is multiples larger than its nearest rivals and will continue to invest aggressively to maintain its competitive edge.
See More
AI Startup Sierra Raises $950 Million in Series E Funding
- Record Funding Round: Sierra raised $950 million in its latest funding round, pushing its valuation from $10 billion to $15.8 billion, highlighting investors' strong interest in the AI sector and their pursuit of emerging market leaders.
- Diverse Clientele: The startup serves major enterprises like Prudential, Cigna, Blue Cross Blue Shield, and Rocket Mortgage, reaching over 40% of Fortune 50 companies, which underscores its market leadership in AI customer service.
- Rapid Revenue Growth: Sierra achieved over $150 million in annual recurring revenue (ARR) within eight quarters, an unprecedented growth rate in traditional software, reflecting intense market demand for its offerings.
- Expansive Market Potential: Founder Bret Taylor estimates that $400 billion is spent annually on customer service, and as AI agents become more prevalent, Sierra is focused on maintaining its competitive edge in an increasingly crowded market.
See More
